foxo4-dri senolytic 2024 peptide 2023 inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis Senolytics: charting a new course – The FOXO4 peptide in a

Read review Dihexa for Endometriosis Brain Fog The November 2025 Lancet O&G/WH 'overlooked symptom' commentary from Edinburgh EXPPECT, the April 2025 Horn FACT-Cog 1,239-patient survey (~80% perceived cognitive impairment), the March 2025 NICE TA1057 Ryeqo approval (first daily pill on NHS), the April 2024 NICE NG73 update, the April 2026 renewed Womens Health Strategy with 117 action points, the 2023 Greaves CNS-wide glial activation mouse model, the BDNF/TrkB central-sensitisation directionality paradox, and the ~1.5 million UK women affected

the FDA has stated it lacks sufficient information to know whether the substance would cause harm when administered to humans Evidence snapshot: The evidence base is almost entirely preclinical, decades of animal (largely rat) studies, mostly from one Croatian research group (Sikiric et al., University of Zagreb), with a single small human trial under the brand name "Bepecin" (around 2015) that did not lead to any FDA-approved use

Add peptides to the same shipment

Licensed alternatives for weight management, including semaglutide (Wegovy) and liraglutide (Saxenda), are available through regulated NHS and private pathways following NICE appraisal

How it works BPC-157 signals blood-vessel cells to relax existing vessels, move into damaged tissue, and form new capillaries